BMY Jan 2026 33.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 11:31AM EDT. Market open.
| Previous close | 10.25 |
| Open | 9.95 |
| Bid | 8.00 |
| Ask | 11.50 |
| Strike | 33.00 |
| Expiry date | 2026-01-16 |
| Day's range | 9.95 - 10.25 |
| Contract range | N/A |
| Volume | |
| Open interest | 120 |
Business WireBristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
PRINCETON, N.J., June 03, 2024--Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations...
Business WireKRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
PRINCETON, N.J., June 01, 2024--KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced....
ZacksBristol Myers (BMY) Gets EC Nod for Opdivo Label Expansion
Bristol Myers' (BMY) Opdivo combination regimen receives the European Commission's approval for the first-line treatment of unresectable or metastatic urothelial carcinoma.
© 2024 Yahoo. All rights reserved.